http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 12:32:48 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26538825.html <p> NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26538825.html Fri, 22 May 2026 08:30:00 -0400 O.46871614 SDGR http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26538825.html <p> NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26538825.html Fri, 22 May 2026 08:30:00 -0400 O.46871614 SDGR http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26538825.html <p> NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26538825.html Fri, 22 May 2026 08:30:00 -0400 O.46871614 SDGR http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26538825.html <p> NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26538825.html Fri, 22 May 2026 08:30:00 -0400 O.46871614 SDGR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Schrodinger%2C+Inc.+++++++++For%3A+May+18/26528673.html si-local-file:///var/storage/secattach/20260520/26528673.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Schrodinger%2C+Inc.+++++++++For%3A+May+18/26528673.html Wed, 20 May 2026 16:20:00 -0400 O.46871614 SDGR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Schrodinger%2C+Inc.+++++++++For%3A+May+18/26528673.html si-local-file:///var/storage/secattach/20260520/26528673.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Schrodinger%2C+Inc.+++++++++For%3A+May+18/26528673.html Wed, 20 May 2026 16:20:00 -0400 O.46871614 SDGR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Schrodinger%2C+Inc.++++++++++++++++++++++Filed+by%3A+Rubric+Capital+Management+LP/26505446.html si-local-file:///var/storage/secattach/20260515/26505446.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Schrodinger%2C+Inc.++++++++++++++++++++++Filed+by%3A+Rubric+Capital+Management+LP/26505446.html Fri, 15 May 2026 16:15:00 -0400 O.46871614 SDGR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Schrodinger%2C+Inc.++++++++++++++++++++++Filed+by%3A+Rubric+Capital+Management+LP/26505446.html si-local-file:///var/storage/secattach/20260515/26505446.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Schrodinger%2C+Inc.++++++++++++++++++++++Filed+by%3A+Rubric+Capital+Management+LP/26505446.html Fri, 15 May 2026 16:15:00 -0400 O.46871614 SDGR http://www.streetinsider.com/Analyst+PT+Change/Schrodinger+%28SDGR%29+PT+Lowered+to+%2417+at+Morgan+Stanley/26490876.html Morgan Stanley analyst Sean Laaman lowered the price target on Schrodinger (NASDAQ: SDGR) to $17.00 (from $19.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Schrodinger+%28SDGR%29+PT+Lowered+to+%2417+at+Morgan+Stanley/26490876.html Thu, 14 May 2026 08:53:26 -0400 SDGR http://www.streetinsider.com/Earnings/Schrodinger+Inc.+%28SDGR%29+Misses+Q1+EPS+by+17c/26435840.html <p>Schrodinger Inc. (NASDAQ: SDGR) reported Q1 EPS of ($0.81), $0.17 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $58.6 million versus the consensus estimate of $48.12 million.</p><p><strong>Outlook:</strong></p><p>As of May 5, 2026, Schrödinger maintained its previously issued financial guidance for the fiscal year ending December 31, 2026:</p><p>ACV is expected to range from $218 million to $228 million, representing 10-15% growth over 2025.<br />Drug discovery revenue is expected to range from $55 million to $65 million.<br />Operating expenses are expected to be less than 2025.</p><p>For the second quarter of 2026, ACV is expected to range from http://www.streetinsider.com/Earnings/Schrodinger+Inc.+%28SDGR%29+Misses+Q1+EPS+by+17c/26435840.html Tue, 05 May 2026 16:41:27 -0400 SDGR http://www.streetinsider.com/Guidance/Schrodinger+Inc.+%28SDGR%29+Misses+Q1+EPS+by+17c/26435840.html <p>Schrodinger Inc. (NASDAQ: SDGR) reported Q1 EPS of ($0.81), $0.17 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $58.6 million versus the consensus estimate of $48.12 million.</p><p><strong>Outlook:</strong></p><p>As of May 5, 2026, Schrödinger maintained its previously issued financial guidance for the fiscal year ending December 31, 2026:</p><p>ACV is expected to range from $218 million to $228 million, representing 10-15% growth over 2025.<br />Drug discovery revenue is expected to range from $55 million to $65 million.<br />Operating expenses are expected to be less than 2025.</p><p>For the second quarter of 2026, ACV is expected to range from http://www.streetinsider.com/Guidance/Schrodinger+Inc.+%28SDGR%29+Misses+Q1+EPS+by+17c/26435840.html Tue, 05 May 2026 16:41:27 -0400 SDGR